Literature DB >> 30721105

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.

Ioannis Papageorgiou1,2, Michael R Loken3, Lisa Eidenschink Brodersen3, Mohammed Gbadamosi1,2, Geoffrey L Uy4, Soheil Meshinchi5, Jatinder K Lamba1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30721105      PMCID： PMC7153571          DOI： 10.1080/10428194.2019.1569232

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  13 in total

1.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Authors:  Kelly J Norsworthy; Chia-Wen Ko; Jee Eun Lee; Jiang Liu; Christy S John; Donna Przepiorka; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2018-04-12

Review 2.  Nonsense-mediated mRNA decay - mechanisms of substrate mRNA recognition and degradation in mammalian cells.

Authors:  Christoph Schweingruber; Simone C Rufener; David Zünd; Akio Yamashita; Oliver Mühlemann
Journal:  Biochim Biophys Acta       Date:  2013-02-20

Review 3.  Investigational CD33-targeted therapeutics for acute myeloid leukemia.

Authors:  Roland B Walter
Journal:  Expert Opin Investig Drugs       Date:  2018-03-15       Impact factor: 6.206

Review 4.  Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.

Authors:  I D Bernstein
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

5.  CD33 as a target for selective ablation of acute myeloid leukemia.

Authors:  Irwin D Bernstein
Journal:  Clin Lymphoma       Date:  2002-03

6.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jatinder K Lamba; Lata Chauhan; Miyoung Shin; Michael R Loken; Jessica A Pollard; Yi-Cheng Wang; Rhonda E Ries; Richard Aplenc; Betsy A Hirsch; Susana C Raimondi; Roland B Walter; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

7.  Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.

Authors:  Leslie Mortland; Todd A Alonzo; Roland B Walter; Robert B Gerbing; Amit K Mitra; Jessica A Pollard; Michael R Loken; Betsy Hirsch; Susana Raimondi; Janet Franklin; Stanley Pounds; Xueyuan Cao; Jeffrey E Rubnitz; Raul C Ribeiro; Alan Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 8.  NMD: a multifaceted response to premature translational termination.

Authors:  Stephanie Kervestin; Allan Jacobson
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-17       Impact factor: 94.444

9.  Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.

Authors:  I D Bernstein; J W Singer; R G Andrews; A Keating; J S Powell; B H Bjornson; J Cuttner; V Najfeld; G Reaman; W Raskind
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

10.  FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.

Authors:  Emily Y Jen; Chia-Wen Ko; Jee Eun Lee; Pedro L Del Valle; Antonina Aydanian; Charles Jewell; Kelly J Norsworthy; Donna Przepiorka; Lei Nie; Jiang Liu; Christopher M Sheth; Marjorie Shapiro; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2018-02-23       Impact factor: 12.531
View more
  5 in total

Review 1.  Evaluation of CD33 as a genetic risk factor for Alzheimer's disease.

Authors:  Steven Estus; Benjamin C Shaw; Nicholas Devanney; Yuriko Katsumata; Eileen E Press; David W Fardo
Journal:  Acta Neuropathol       Date:  2019-04-04       Impact factor: 17.088

2.  CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Lata Chauhan; Miyoung Shin; Yi-Cheng Wang; Michael Loken; Jessica Pollard; Richard Aplenc; Betsy A Hirsch; Susana Raimondi; Rhonda E Ries; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Jatinder K Lamba
Journal:  JCO Precis Oncol       Date:  2019-05-23

3.  A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Authors:  Mohammed O Gbadamosi; Vivek M Shastri; Abdelrahman H Elsayed; Rhonda Ries; Oluwaseyi Olabige; Nam H K Nguyen; Angelica De Jesus; Yi-Cheng Wang; Alice Dang; Betsy A Hirsch; Todd A Alonzo; Alan Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Leukemia       Date:  2022-06-10       Impact factor: 12.883

Review 4.  The role of innate immune genes in Alzheimer's disease.

Authors:  Ana Griciuc; Rudolph E Tanzi
Journal:  Curr Opin Neurol       Date:  2021-04-01       Impact factor: 6.283

5.  The CD33 short isoform is a gain-of-function variant that enhances Aβ1-42 phagocytosis in microglia.

Authors:  Abhishek Bhattacherjee; Jaesoo Jung; Sameera Zia; Madelene Ho; Ghazaleh Eskandari-Sedighi; Chris D St Laurent; Kelli A McCord; Arjun Bains; Gaurav Sidhu; Susmita Sarkar; Jason R Plemel; Matthew S Macauley
Journal:  Mol Neurodegener       Date:  2021-03-25       Impact factor: 14.195
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.